



**NCI-FREDERICK
INSTITUTIONAL BIOSAFETY COMMITTEE**

Minutes
January 15, 2008
NCI-Frederick

The NCI-Frederick Institutional Biosafety Committee was convened at 12:04 p.m. in the Building 549 Executive Boardroom with the following members in attendance:

Ms. Theresa Bell, Secretary	Dr. Henry Hearn
Dr. Randall Morin	Dr. David Garfinkel
Ms. Alberta Peugeot	Dr. Stephen Creekmore
Dr. Bruce Crise	Dr. Stephen Hughes
Dr. Mike Baseler	Dr. Dan McVicar
Mr. Lucien Winegar	

Members not in attendance: Dr. Melinda Hollingshead, Ms. Dianna Boissey

Others in attendance: Ms. Cara Leitch, Dr. Robert Thomas, Dr. Scott Keimig

New Business

Lockett (07-67 and 07-68 – Post-embedding immuno-electron microscopy)

- A Certificate of Analysis must be provided regarding *B. anthracis* and *Y. pestis*. Test data for inactivation and confirmation that the material is free of any biohazardous elements are needed for each shipment when material is sent from USAMRIID. BSL-2 requirements are appropriate if assurances can be made that the material is really inactivated
- Lab techs must know the signs and symptoms of cutaneous *B. anthracis* exposure. Training is to be defined and documented.
- It is not clear if spores are involved in the work.
- The employee roster and research locations form must be completed.

Dr. Crise made a motion to defer approval, Dr. Morin seconded and all were in favor.

Schetter (07-69 – The ability of microRNA-21 inhibition to alter the effectiveness of chemotherapeutic agents on tumorigenic cell lines transplanted into SCID mice)

- The ASP addresses 5 FU, but the IBC document does not. Although 5 FU is not a biological concern, the IBC would like to know how much 5FU will be used since it is pretty toxic.
- How the animal facility workers will protect themselves from inhaling and/or sticking themselves with 5 FU must be addressed.
- It is unclear whether any materials are to be extracted from the mice after they are injected with the transfected human cell lines?
- E6b1 is not clear - regardless of whether the material going into the animal is BSL-2 all material coming out of the animals should be treated as BSL-2.

Dr. Garfinkel made a motion to conditionally approve the registration pending responses to the questions above, Mr. Winegar seconded and all were in favor.

Trinchieri (07-70 – *Toxoplasma gondii* and the innate response)

- A5a: The collaborators of this project should be involved with training the laboratory workers.
- The SOP is pretty basic. It should include specific information regarding potential exposures to *Toxoplasma gondii* and how the hazards will be mitigated. The SOP should also include a statement regarding the hazards to women who are pregnant, women who are planning to get pregnant, and husbands working in the lab who have a pregnant wife at home.
- C9a: Are the cells frozen?
- C13a: The IBC recommends killing the cultures of organisms prior to removing from the BSC to bring out onto the open bench top for viewing under the microscope.
- Medical surveillance should be offered to the individuals working with this material
- Documentation in writing is necessary that training has been completed and each individual has been offered a titer.
- E9: How will the animal cages be dumped safely to prevent hazardous aerosols from being generated? Disposable cages should be considered to avoid the hazard completely.

Dr. Hughes made a motion to defer approval, Dr. Creekmore seconded and all were in favor.

Outstanding Items

- Ms. Bell briefed the IBC on the outstanding items.
- All PIs who received a delinquency notice last month have contacted the IBC Secretary for a path forward.

Other Business

- The Bloodborne Pathogen Program is currently 95% compliant. Efforts are continuously made to ensure individuals on the program take their training in a timely manner.
- A new IBC member is needed, preferably with a virology background and animal experience. IBC members were asked to provide suggestions to the IBC Secretary.
- The IBC form will be updated to reflect changes proposed by the IP Office.
- The Vaccination Policy will be distributed again for revisions before final approval.
- An ABSA Journal Article will be emailed out to each IBC member for review and input.

The meeting ended at 1:26 p.m.

Theresa D. Bell, MPH, CBSP
IBC Secretary
Biological Safety Officer, EHS

Ms. Cara Leitch
IBC Coordinator
Sr. Safety Specialist, EHS

APPROVED:

Randall S. Morin, Dr. P.H.
Chairman, NCI-Frederick IBC
Director, EHS

Date

xc: Dr. Reynolds
Mr. Wheatley
Dr. Arthur
Mr. Butfer